Skip to main content
Bora Pharmaceuticals Co., Ltd. logo

Bora Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 6472 ISIN · TW0006472004 LEI · 254900MK7O5C2UX1SY03 TW Manufacturing
Open in API
Filings indexed 21 across all filing types
Latest filing 2026-05-04 Regulatory Filings
Country TW Taiwan
Listing TW 6472

About Bora Pharmaceuticals Co., Ltd.

https://bora-corp.com/

Bora Pharmaceuticals Co., Ltd. is a global pharmaceutical service provider that operates through a "dual-engine" business model, integrating comprehensive Contract Development and Manufacturing Organization (CDMO) services with the development and commercialization of specialty pharmaceuticals. The company provides end-to-end solutions ranging from formulation development and clinical trial materials to large-scale commercial manufacturing. Its technical capabilities encompass a diverse array of dosage forms, including oral solids, liquids, and semi-solids. With a manufacturing footprint spanning multiple continents, the company serves global markets by leveraging advanced production technologies and rigorous quality management systems. Bora Pharmaceuticals focuses on strategic growth through acquisitions and partnerships, aiming to enhance manufacturing efficiency and accelerate the delivery of complex therapeutic treatments to patients worldwide.

Recent filings

Filing Released Lang Actions
員工認股權憑證
Regulatory Filings
2026-05-04 Chinese
115年4月24日內部人設質解質
Director's Dealing Classification · 85% confidence The document is a table of share pledge details by a director-level individual (insider) reporting the number of shares pledged, released, and cumulative pledged shares. This falls under insider share transactions (director’s dealing). Therefore, the correct classification is DIRS.
2026-04-27 Chinese
115年4月23日內部人設質解質
Director's Dealing Classification · 90% confidence The document is from Taiwan’s Market Observation Post System showing a table of share pledges/unpledges by a director-related party (設質人 “director/legal representative”), detailing the number of shares pledged and released on specific dates. This is an insider share transaction report by a company director, fitting the “Director’s Dealing” category.
2026-04-24 Chinese
公告本公司董事會決議召開115年股東常會相關事宜 (更新召集事由三)
Proxy Solicitation & Information Statement Classification · 85% confidence The document is a formal announcement by the board of directors calling the 115th shareholders’ meeting, listing date, location, agenda items, reasons for convening, and proxy‐related details. It is not the AGM materials themselves (AGM‐R) nor a post‐meeting voting results notice (DVA). It serves as information sent to shareholders to inform and solicit votes for the meeting, matching the Proxy Solicitation & Information Statement category.
2026-04-20 Chinese
公告本公司國內第五次無擔保轉換公司債收足應募價款
Capital/Financing Update Classification · 85% confidence The document is an announcement by a listed company (保瑞藥業) that its domestic fifth unsecured convertible corporate bond subscription money has been fully collected and deposited. This relates to the company’s fundraising and issuance of convertible bonds (a financing activity). Therefore, it falls under Capital/Financing Update.
2026-04-13 Chinese
115年04月僑外投資持股
Regulatory Filings Classification · 71% confidence The document is a statutory disclosure of Taiwan-listed company shareholdings by overseas Chinese and Mainland China investors as of a specified date. It is not announcing a shareholder meeting result, not an earnings report, not a threshold crossing by a specific major holder, nor a capital change or AGM material. It is a general regulatory report required by the exchange (公開資訊觀測站) providing shareholding statistics. This falls under the catch-all “Regulatory Filings” category (RNS).
2026-04-13 Chinese

Browse filings by year

1 year

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.